Call +1 (833) 552-7181 or Contact us Earn $25 in coupons on your first order with Aladdin!
Toggle Nav
My Cart
Search
Advanced Search
Menu
Sign In
྾
main product photo

MS15 , CAS No.M612084, Inhibitor of AKT serine/threonine kinase 1;Inhibitor of AKT serine/threonine kinase 2;Inhibitor of AKT serine/threonine kinase 3

Item Number
M612084
Grouped product items
SKUSizeAvailabilityPrice Qty
M612084-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$1,334.90
M612084-25mg
25mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$2,000.90
Add to Wish List Compare
Bulk Order  SDS  DATASHEET
View related series
AKT serine/threonine kinase 1 Inhibitor AKT serine/threonine kinase 2 Inhibitor AKT serine/threonine kinase 3 Inhibitor

Basic Description

Synonymscompound 62
Specifications & PurityMoligand™
GradeMoligand™
Action TypeINHIBITOR
Mechanism of actionInhibitor of AKT serine/threonine kinase 1;Inhibitor of AKT serine/threonine kinase 2;Inhibitor of AKT serine/threonine kinase 3

Associated Targets(Human)

AKT3 Tchem RAC-gamma serine/threonine-protein kinase (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
AKT2 Tchem RAC-beta serine/threonine-protein kinase (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
AKT1 Tchem RAC-alpha serine/threonine-protein kinase (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
AKT2 Tchem Serine/threonine-protein kinase AKT2 (4301 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
AKT3 Tchem Serine/threonine-protein kinase AKT3 (3157 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
AKT1 Tchem Serine/threonine-protein kinase AKT (9192 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PC-3 (62116 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SW-620 (52400 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
AKT1S1 Tchem Proline-rich AKT1 substrate 1 (25 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Names and Identifiers

INCHI InChI=1S/C64H79N11O5S/c1-41(44-22-24-45(25-23-44)56-42(2)69-40-81-56)70-61(79)53-38-49(76)39-74(53)62(80)57(63(3,4)5)73-55(78)20-12-10-8-6-7-9-11-13-35-67-54(77)32-21-43-17-14-18-46(37-43)51-30-31-52-60(71-51)75(59(72-52)50-19-15-36-68-58(50)65)48-28-26-47(27-29-48)64(66)33-16-34-64/h14-15,17-19,22-31,36-37,40-41,49,53,57,76H,6-13,16,20-21,32-35,38-39,66H2,1-5H3,(H2,65,68)(H,67,77)(H,70,79)(H,73,78)/t41-,49+,53-,57+/m0/s1
InChi Key XYGBNRINQSQNJG-IQDHSYJRSA-N
Canonical SMILES O=C(NCCCCCCCCCCC(=O)N[C@@H](C(C)(C)C)C(=O)N1[C@H](C(=O)N[C@@H](C)c2ccc(c3c(C)ncs3)cc2)C[C@@H](O)C1)CCc1cc(c2nc3c(nc(c4c(N)nccc4)n3c3ccc(C4(N)CCC4)cc3)cc2)ccc1
Isomeric SMILES CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNC(=O)CCC4=CC(=CC=C4)C5=NC6=C(C=C5)N=C(N6C7=CC=C(C=C7)C8(CCC8)N)C9=C(N=CC=C9)N)O
PubChem CID 165368938

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Related Documents

 SDS

 Specification Sheet

References

1. Yu X, Xu J, Cahuzac KM, Xie L, Shen Y, Chen X, Liu J, Parsons RE, Jin J.  (2022)  Novel Allosteric Inhibitor-Derived AKT Proteolysis Targeting Chimeras (PROTACs) Enable Potent and Selective AKT Degradation in KRAS/BRAF Mutant Cells..  J Med Chem,  129  (3): (589-97).  [PMID:36197750]

Solution Calculators

Privacy Policy Website Terms of Use Return policy Terms and Conditions of Sale Cookie Policy Sales Policy
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Copyright © 2023-present Aladdin Scientific Corp . All rights reserved.